ADMA Biologics Faces Class Action Over Alleged Disclosure Failures

Investors who lost more than $100,000 in ADMA Biologics securities between August 2024 and March 2026 face an August 10 deadline to file as lead plaintiffs. The lawsuit, pending in New Jersey, alleges the company misled shareholders regarding its internal controls, revenue practices, and undisclosed related-party transactions.

The litigation, filed under the case Mazzarino v. ADMA Biologics, Inc., contends that the pharmaceutical firm and its executives violated federal securities laws by concealing material information throughout the class period. Specifically, the complaint alleges that ADMA utilized channel stuffing to artificially inflate revenue figures and failed to maintain adequate internal controls, rendering their public disclosures about business operations fundamentally inaccurate.

Shareholders impacted by these alleged omissions are directed to ClaimsFiler, a service providing information on class action settlements, to evaluate their legal standing. Attorneys at Kahn Swick & Foti, LLC are currently reviewing potential claims for those who acquired ADMA stock during the specified window. Investors seeking to participate or review their options can access case details through the firm’s portal or by contacting the legal team directly.